SCM
CRBP icon

Sterling Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Sterling Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-86
Closed -$457 – 3291
2025
Q1 		$457 Sell
86
-58
-40% -$512 ﹤0.01% 2970
2024
Q4 		$1.7K Buy
144
+125
+658% +$2.1K ﹤0.01% 2820
2024
Q3 		$392 Buy
+19
New +$972 ﹤0.01% 2966

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

Sterling Capital Management's CRBP Position: Q2 2025 in Review

Sterling Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2025, closing a stake of 86 shares — an estimated $457 sold.

Sterling Capital Management first reported a position in CRBP in Q3 2024 and held it in 3 quarters. The position peaked at $1.7K in Q4 2024. 80 funds tracked by Wall St. Rank hold CRBP as of Q2 2025.

  • Sterling Capital Management reported no remaining Corbus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 86 Corbus Pharmaceuticals shares in Q2 2025, an estimated $457.
  • Sterling Capital Management first reported a position in Corbus Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Corbus Pharmaceuticals position peaked at $1.7K in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.